TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Inclusion criteria

• Histologically confirmed peripheral T-cell lymphoma (PTCL), including PTCL-NOS, AITL, ALCL, or NKTCL
• Received at least one prior systemic therapy and prior exposure to at least one novel agent (e.g., chidamide, pralatrexate, brentuximab vedotin, etc.) or refractory/intolerant to such therapies
• Age ≥18 years
• ECOG performance status 0-1
• At least one measurable lesion per Lugano 2014 criteria (lymph node ≥1.5 cm in longest diameter or extranodal lesion ≥1.0 cm)
• Adequate organ function, defined as: ANC ≥1.5 × 10⁹/L, Platelets ≥100 × 10⁹/L, Hemoglobin ≥100 g/L, Total bilirubin ≤1.5 × ULN, ALT/AST ≤2.5 × ULN (≤5 × ULN if liver involvement), Creatinine clearance ≥50 mL/min (Cockcroft-Gault), LVEF ≥50%, QTcF <450 ms (male), <470 ms (female)
• Willingness to provide archival or fresh tumor tissue
• Life expectancy ≥3 months

Exclusion criteria

• Prior treatment with EZH2 or EZH1/2 inhibitors resulting in disease progression (intolerance permitted)
• Known central nervous system involvement of lymphoma
• Active uncontrolled infection requiring systemic therapy
• Significant or uncontrolled cardiovascular disease
• Prior allogeneic stem cell transplantation or autologous stem cell transplantation within 90 days prior to first dose
• Pregnancy or lactation, or unwillingness to use effective contraception
• Other malignancies within 5 years, except adequately treated basal cell carcinoma, squamous cell carcinoma, carcinoma in situ, or thyroid carcinoma
• Patients planned to receive mitoxantrone liposomal therapy with prior cumulative doxorubicin exposure ≥350 mg/m² (or equivalent anthracycline exposure)